<DOC>
	<DOCNO>NCT01484626</DOCNO>
	<brief_summary>The purpose study determine safety efficacy use Bendamustine combination commonly use combination chemotherapy treat relapse refractory multiple myeloma . The study conduct two phase . Participants phase I receive 1 4 escalating dos bendamustine . Once maximum tolerate dose bendamustine determine phase II trial begin . Participants phase II receive maximum tolerate dose bendamustine combination standard care chemotherapy .</brief_summary>
	<brief_title>Bendamustine , Wkly Bortezomib , Lenalidomide Dexamethasone Multiple Myeloma</brief_title>
	<detailed_description>Multiple myeloma multi-organ neoplastic disorder cause clonal proliferation plasma cell . It incidence 4.5/100,000 per year U.S. , make second common hematologic malignancy . For many year , alkylating agent backbone treatment . The combination melphalan prednisone , many year , standard care patient candidate autologous transplantation . Melphalan continue primary conditioning agent autologous transplant , cyclophosphamide also gain foothold treatment disease . The introduction novel agent fundamentally change landscape treat disease , although true effect survival yet know . Immunomodulatory agent proteosome inhibitor , include thalidomide , lenalidomide bortezomib , use newly diagnose relapsed patient . Currently , intense clinical research optimal way combine novel agent traditional backbone treatment - include alkylators , one another , eventually , subsequent iteration class drug . However , despite therapeutic excitement surround disease , nearly patient relapse , cure remain elusive goal rare handful .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Adults relapse and/or refractory myeloma receive 14 prior line therapy must adequate liver renal function ZPS 2 good must measurable disease Peripheral neuropathy grade II high Thrombocytopenia ( platelet le 50,000/uL ) Neutropenia ( ANC &lt; 1000/uL ) AST ALT &gt; 2.4 X ULN Total bilirubin &gt; 1.5 X ULN Creatinine clearance less 60mL/min ( Phase I ) 40mL/min less ( Phase II ) Patients HIV Patients active hepatitis Pregnant lactate woman Individuals childbearing potential use adequate contraception Individuals unable provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Relapsed Multiple Myeloma</keyword>
	<keyword>Refractory Multiple Myeloma</keyword>
	<keyword>Bendamustine</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Treanda</keyword>
	<keyword>Velcade</keyword>
	<keyword>Revlimid</keyword>
</DOC>